CA2275912A1 - Preparation de gabapentine - Google Patents

Preparation de gabapentine Download PDF

Info

Publication number
CA2275912A1
CA2275912A1 CA002275912A CA2275912A CA2275912A1 CA 2275912 A1 CA2275912 A1 CA 2275912A1 CA 002275912 A CA002275912 A CA 002275912A CA 2275912 A CA2275912 A CA 2275912A CA 2275912 A1 CA2275912 A1 CA 2275912A1
Authority
CA
Canada
Prior art keywords
gabapentin
solvent
butanol
hydrochloride
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002275912A
Other languages
English (en)
Inventor
Michael Pesachovich
Claude Singer
Gideon Pilarski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2275912A1 publication Critical patent/CA2275912A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé permettant de convertir du chlorhydrate de gabapentine essentiellement exempt de sels inorganiques en gabapentine de forme (II). Ce procédé comprend les étapes consistant; 1) à obtenir du chlorhydrate de gabapentine essentiellement exempt de sels inorganiques; 2) à mélanger une solution dudit chlorhydrate de gabapentine avec un amine supplémentaire dans un premier solvant, afin d'obtenir un précipité renfermant de la gabapentine; puis 3) à récupérer la gabapentine de forme II à partir dudit précipité. La gabapentine précipitée constitue une nouvelle forme polymorphe de gabapentine, qui possède une structure cristalline caractérisée par de nouvelles crêtes dans le diagramme de diffraction des rayons X de la poudre et dans le spectre infrarouge à transformée de Fourier. Cette nouvelle forme de gabapentine est ici désignée par la gabapentine de forme III. L'étape de récupération peut par exemple comprendre un ou deux autres procédés, qui consistent à mettre en suspension la gabapentine de forme II dans du méthanol, puis à filtrer cette suspension pour obtenir de la gabapentine de forme II, ou à rendre la gabapentine de forme III soluble dans le méthanol en la faisant bouillir à reflux avant de la faire refroidir pour obtenir la gabapentine de forme II par cristallisation.
CA002275912A 1996-12-24 1997-12-24 Preparation de gabapentine Abandoned CA2275912A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL119890 1996-12-24
IL11989096A IL119890A (en) 1996-12-24 1996-12-24 Gabapentin form iii and preparation of gabapentin form ii
PCT/US1997/023164 WO1998028255A1 (fr) 1996-12-24 1997-12-24 Preparation de gabapentine

Publications (1)

Publication Number Publication Date
CA2275912A1 true CA2275912A1 (fr) 1998-07-02

Family

ID=11069615

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002275912A Abandoned CA2275912A1 (fr) 1996-12-24 1997-12-24 Preparation de gabapentine

Country Status (7)

Country Link
EP (1) EP0950044A4 (fr)
AU (1) AU5799098A (fr)
CA (1) CA2275912A1 (fr)
DE (1) DE97954134T1 (fr)
ES (1) ES2204362T1 (fr)
IL (1) IL119890A (fr)
WO (1) WO1998028255A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2137137B1 (es) * 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
IT1311984B1 (it) * 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
AU4334900A (en) 1999-04-09 2000-11-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
ES2164527B1 (es) * 1999-04-26 2003-04-01 Medichen S A Procedimiento de obtencion de gabapentina de calidad farmaceutica.
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
EP1430893A1 (fr) * 2000-06-16 2004-06-23 Teva Pharmaceutical Industries Ltd. Gabapentin stable contenant plus de 20 ppm d'ions chlore
AU2001268426A1 (en) * 2000-06-16 2002-01-02 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 2o ppm of chlorine ion
SK302003A3 (en) * 2000-06-16 2003-07-01 Teva Pharma Stable gabapentin having pH within a controlled range
EP1384473A1 (fr) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Gabapentin stable contenant plus de 20 ppm d'ions chlore
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
US6800782B2 (en) 2001-10-09 2004-10-05 Warner-Lambert Co. Anhydrous crystalline forms of gabapentin
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
ATE418535T1 (de) 2002-11-18 2009-01-15 Nicholas Piramal India Ltd Verbessertes verfahren zur herstellung von gabapentin
ATE455089T1 (de) * 2002-11-20 2010-01-15 Hikal Ltd Verfahren zur herstellung von aminomethylcycloalkan-essigsäuren
WO2004093780A2 (fr) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Processus de preparation de gabapentine forme ii
WO2004093779A2 (fr) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Procede relatif a l'elaboration de gabapentine de forme-ii
WO2004106281A1 (fr) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Gabapentine cristallin
WO2004110342A2 (fr) * 2003-06-12 2004-12-23 Matrix Laboratories Ltd Nouveau polymorphe de gabapentine et sa conversion en gabapentine de forme ii
WO2004110981A1 (fr) * 2003-06-12 2004-12-23 Matrix Laboratories Ltd Procede permettant la preparation de gabapentine de forme ii
US7169812B2 (en) 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
ITMI20040579A1 (it) 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
GB0415076D0 (en) * 2004-07-05 2004-08-04 Sandoz Ind Products S A Process for the preparation of gabapentin
GB0416228D0 (en) * 2004-07-20 2004-08-25 Sandoz Ind Products S A Process for the preparation of gabapentin
WO2008106217A1 (fr) * 2007-02-28 2008-09-04 Teva Pharmaceutical Industries Ltd. Préparation de gabapentine par extraction liquide-liquide
EP2183211A1 (fr) 2007-07-27 2010-05-12 Medichem, S.A. Procédé de préparation de la forme polymorphe ii de la gabapentine
CN102363598B (zh) * 2011-11-25 2014-02-12 浙江精进药业有限公司 高纯度加巴喷丁的制备方法
ITMI20131757A1 (it) 2013-10-22 2015-04-23 Zach System Spa Processo di preparazione di gabapentina

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte

Also Published As

Publication number Publication date
ES2204362T1 (es) 2004-05-01
EP0950044A1 (fr) 1999-10-20
IL119890A0 (en) 1997-03-18
EP0950044A4 (fr) 2003-03-26
WO1998028255A1 (fr) 1998-07-02
DE97954134T1 (de) 2004-04-15
IL119890A (en) 2002-03-10
AU5799098A (en) 1998-07-17

Similar Documents

Publication Publication Date Title
CA2275912A1 (fr) Preparation de gabapentine
US6255526B1 (en) Preparation of gabapentin
EA015426B1 (ru) Способ получения галогенидов n-алкилнальтрексона
US5399765A (en) Enantioselective preparation of optically pure albuterol
EP2327708A2 (fr) Procédé de purification d'adefovir dipivoxil
WO2015044853A2 (fr) Procédé de préparation de fumarate de diméthyle
CA2333408A1 (fr) Polymorphe de gabapentine non hydratee, son procede d'obtention et son utilisation pour l'obtention de gabapentine a usage pharmaceutique
JPS585904B2 (ja) グアニジン及びその塩類の製造方法
CN109836424B (zh) 一种环保型茶碱钠盐甲基化制备咖啡因的方法
JP3182946B2 (ja) Ｎ−（α−アルコキシエチル）ホルムアミドの製造方法
WO2008096373A2 (fr) Procédé de synthèse de polymorphes de natéglinide extrêmement pure
CN114008023B (zh) 索吡溴铵的晶型及其制备方法
CN109689620B (zh) 拆分巴氯芬盐的方法
JP3318992B2 (ja) Ｎ−（α−アルコキシエチル）ホルムアミドの製造方法
KR101287425B1 (ko) 글리세릴 포스포릴 콜린 ii형 결정의 제조방법
US20080146805A1 (en) Process for the Production of Levorphanol and Related Compounds
JP2988019B2 (ja) Ｎ−アルキルアミノエタンスルホン酸ナトリウムの製造方法
CN1315777C (zh) 旋光二酰基酒石酸的回收方法
JP3042122B2 (ja) Ｎ−シアノアセトアミジン誘導体の製造方法
KR101287423B1 (ko) 글리세릴 포스포릴 콜린의 ii형 결정
JP3848714B2 (ja) エチレンジアミン−ｎ，ｎ’−ジコハク酸およびその第二鉄錯塩の製法
CN113087680A (zh) Dota晶型及其制备方法
JPH1180099A (ja) （１ｓ，２ｒ）−１−アミノ−２−インダノール−（ｒ，ｒ）−タートレート メタノール溶媒和物の調製方法
WO2006090208A1 (fr) Procede et methodes de preparation de gabapentine et de produits intermediaires du gabapentine
JP2770512B2 (ja) アミノエチルスルホン酸アルカリ金属塩類の精製方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued